Results 41 to 50 of about 4,829 (180)

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

open access: yesAdvances in Hematology, 2022
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s ...
Maroun Bou Zerdan   +4 more
doaj   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

open access: yesBritish Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz   +45 more
wiley   +1 more source

Ibrutinib and standard immunochemotherapy in younger, high‐risk patients with diffuse large B‐cell lymphoma: A phase II study of GLA

open access: yesBritish Journal of Haematology, EarlyView.
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov   +19 more
wiley   +1 more source

Complex karyotype and non‐BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima   +20 more
wiley   +1 more source

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas

open access: yesForum of Clinical Oncology, 2017
In normal B-cells, Bruton tyrosine kinase (Btk), a non-receptor tyrosine kinase involved in B-cell receptor (BCR) signalling, is essential for cell survival and maturation. Not surprisingly, Btk is also implicated in the pathogenesis of B-cell lymphomas,
Sklavenitis-Pistofidis R.   +3 more
doaj   +1 more source

CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart   +15 more
wiley   +1 more source

Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta‐Analysis of Clinical Trials

open access: yeseJHaem
Introduction Targeted kinase inhibitors have shown statistically and clinically significant improvements in platelet response among patients with primary ITP, supporting their utility as effective targeted therapeutic strategies.
Ayah Abulehia   +9 more
doaj   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

New anti‐inflammatory and remodelling drugs for unmet clinical needs in severe asthma and chronic obstructive pulmonary disease (COPD)

open access: yesBritish Journal of Pharmacology, EarlyView.
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley   +1 more source

Home - About - Disclaimer - Privacy